GLP-1 Half-Life: Why Weekly Shots Overlap

Timing made simple

Your weekly shot is still contributing when the next one arrives. Half-life describes how fast an amount falls, not when a medicine switches off.

That explains overlap and buildup over the first weeks. Feeling hungrier late in the week does not tell you how much medicine is left.

See why hunger can return ↗ Explore the plotter ↗

One-week half-life · simple example

Half left is not switched off

3.1% remains after five weeks in this example — not zero.

Semaglutide, tirzepatide and retatrutide at a glance

Sources: Wegovy label, Zepbound label, retatrutide phase 1b trial. These values are not a potency ranking or a dose conversion. A separate formulation needs its own absorption model.

What “half left” looks like

In the opening example, each week halves what remains: 100% → 50% → 25% → 12.5%. After five weeks, about 3.1% remains. It is an elimination-only illustration, not a full semaglutide injection curve or a clearance deadline.

When doses repeat, the next dose arrives on top of residual drug. With an unchanged schedule, the peaks and troughs move toward a repeating pattern called steady state. Four to five half-lives is a useful approximation for getting close, rather than an exact time at which benefits switch on.

Hungry on day 5 or 6: has it worn off?

People report this pattern, but a chart cannot confirm its cause. Drug concentration falls between weekly injections while appetite also reflects meals, activity, sleep and other factors. Being hungry is not a blood-level test.

Record the day of the injection, appetite pattern and any symptoms across several weeks to discuss with the prescriber. Shortening the interval changes the amount given over time; it is not just moving the same weekly dose on a calendar. For labeled amounts and treatment duration, see the semaglutide guide or tirzepatide guide.

Why can these medicines last for days?

Natural GLP-1 is rapidly broken down. Medicines can be modified to resist degradation and remain in circulation longer. Semaglutide combines sequence changes with a fatty-acid attachment that promotes binding to albumin, a blood protein. The details of the molecule and attachment matter; counting carbon atoms in the side chain is not enough to predict half-life. Original semaglutide discovery paper

DPP-4 inhibitors are a different drug class that affects the breakdown of endogenous incretins. They are not simply oral versions of a long-acting GLP-1 agonist. Long-acting formulations also need not all use the same engineering approach.

Why the peak is later than the injection

An injection is an input event, not necessarily the concentration peak. After a subcutaneous dose, absorption can spread the rise over many hours or days. Therefore, a simple instantaneous-input calculation cannot establish that the real peak is exactly twice the trough.

A lower trough also does not diagnose loss of treatment effect. Appetite, GI effects and weight respond through processes that are not shown by a concentration-only plot. If a change is being considered, use the graph to explain the question to the prescriber rather than to choose an extra dose.

What happens after a dose change or stopping?

A longer half-life can mean slower adjustment after changing or stopping treatment. It does not guarantee greater efficacy or better tolerability. Longer exposure also means a dosing error may need prolonged assessment; “five half-lives” is not a universal recovery, switching, pregnancy or procedure interval.

Titration schedules are supported by product-specific clinical evidence and tolerability goals. Accumulation is part of the explanation, but a starting dose is not biologically inactive and a calendar step is not mandatory when poorly tolerated.

Frequently asked questions

Why can’t I just take a higher dose to start?

Label initiation schedules are designed to manage tolerability while treatment is introduced. A higher first dose changes exposure without recreating the tested gradual introduction.

How long does it take for GLP-1 drugs to leave the body?

The amount declines gradually. Five half-lives leaves about 3.1% under a simple model, not zero. Clinical instructions take precedence over a calculated percentage.

Does the half-life affect weight loss results?

It helps determine exposure, but half-life alone does not rank weight-loss outcomes. Compare appropriately designed clinical trials instead.

Sources

Mechanism, PK and mathematical assumptions

Lau et al., semaglutide design explains structure and binding; its animal PK values are not used as human values. Human values above come from the linked labels and retatrutide trial. The percentage figure uses 100 × 2^(−elapsed half-lives).